Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Aflibercept biosimilar by Celltrion for Diabetic Macular Edema: Likelihood of Approval
Aflibercept biosimilar is under clinical development by Celltrion and currently in Phase III for Diabetic Macular Edema. According to GlobalData,...
Aflibercept biosimilar by Celltrion for Age Related Macular Degeneration: Likelihood of Approval
Aflibercept biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Age Related Macular Degeneration. According to GlobalData,...
Ustekinumab biosimilar by Celltrion for Psoriatic Arthritis: Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Psoriatic Arthritis. According to GlobalData, Pre-Registration drugs...
Ustekinumab biosimilar by Celltrion for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData,...
Ustekinumab biosimilar by Celltrion for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Crohn's Disease (Regional Enteritis). According to GlobalData,...
Ustekinumab biosimilar by Celltrion for Ulcerative Colitis: Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Ulcerative Colitis. According to GlobalData, Pre-Registration drugs...
Tocilizumab biosimilar by Celltrion for Rheumatoid Arthritis: Likelihood of Approval
Tocilizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Rheumatoid Arthritis. According to GlobalData, Pre-Registration drugs...
Risk adjusted net present value: What is the current valuation of Celltrion's Tocilizumab biosimilar?
Tocilizumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Pre-Registration program in Rheumatoid Arthritis. According to Globaldata,...
Omalizumab biosimilar by Celltrion for Allergic Asthma: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Allergic Asthma. According to GlobalData, Pre-Registration drugs...
Omalizumab biosimilar by Celltrion for Food Allergy: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Food Allergy. According to GlobalData, Pre-Registration drugs...
Omalizumab biosimilar by Celltrion for Nasal Polyps (Nasal Polyposis): Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Nasal Polyps (Nasal Polyposis). According to GlobalData,...
Omalizumab biosimilar by Celltrion for Rhinosinusitis: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Rhinosinusitis. According to GlobalData, Pre-Registration drugs for...
Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis. According to GlobalData, Phase I...
Omalizumab biosimilar by Celltrion for Chronic Urticaria Or Hives: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Chronic Urticaria Or Hives. According to GlobalData,...
Ocrelizumab biosimilar by Celltrion for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
Ocrelizumab biosimilar is under clinical development by Celltrion and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS). According...
Denosumab biosimilar by Celltrion for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Post Menopausal Osteoporosis. According to GlobalData, Pre-Registration...
Rituximab biosimilar by Celltrion for Primary CNS Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Celltrion and currently in Phase II for Primary CNS Lymphoma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Celltrion's Denosumab biosimilar?
Denosumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Pre-Registration program in Post Menopausal Osteoporosis. According to...
Denosumab biosimilar by Celltrion for Bone Disorders: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Bone Disorders. According to GlobalData, Phase...